Abstract
Bortezomib (formerly known as PS-341) inhibits the ubiquitin—proteasome pathway with a hypothesized high degree of specificity for cell-cycle proteins. Preclinical activity has been observed in prostate and mammary cancer. Phase I data have defined tolerable toxicity, and thus analysis for brain tumor therapy is warranted. A rat intracranial 9L gliosarcoma model was given 1.0 mg/kg iv of C-14-labeled bortezomib to assess distribution. Intravenous and intratumoral bortezomib administration 10 d after implant was used to assess efficacy. At 1 h, tumor penetration reached 0.2–0.4 μM concentrations with negligible amounts found in the contralateral normal hemisphere. Survivals of rats given bortezomib 0.1 mg/kg iv twice a week and of controls were 20.8 ± 0.5 and 18.5 ± 0.7 d (p = 0.014), respectively. At 0.2 mg/kg, the bortezomib and control survivals were 22 ± 1.5and 16 ± 0.9 d (p = 0.0045), respectively. The single iv median lethal dose was 0.4 mg/ kg. Intratumoral injections had less toxicity than systemic injections, and 0.2 mg/kg of bortezomib given intratumorally provided benefit over vehicle injection, with survivals of 28 ± 6.4 d and 16.5 ± 0.6 d (p = 0.0013), respectively. In vivo, a single iv dose of 0.2 mg/kg of bortezomib increased 9L tumor p21 protein content 6–24 h after exposure; baseline was reached at 48 h, supporting its impact on the cell cycle. Quantification of intrinsic 20 S proteasome activity in human brain tumors may offer insight into which tumors might respond to inhibitors. Mean 20S proteasome specific activity values (in pmol/s/mg protein) from a small series of frozen fresh human specimens of glioblastoma (GBM), anaplastic astrocytoma, oligodendroglioma, adenocarcinoma, schwannoma, and meningioma were 5.0, 4.6,5.2,8.3,12.0, and 14.3, respectively. A range of values (3.5– 8.2), occurred for GBM (n = 5). It is hypothesized that this measurement may be predictive of the responsiveness of GBM to bortezomib. As a first step, a phase I study of the safety and tolerability of bortezomib has been initiated to determine a maximum tolerated dosage (MTD). In the 9L model bortezomib clearly enhances survival, but at high enough doses systemic bortezomib is not without toxicity. The hypothesized function inhibited by the drug, proteasome activity, is measurable. Therefore, with a MTD in hand, a study correlating this quantity as a predictive surrogate marker with efficacy is possible.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Elliott PJ, et al. Clinical development of the first proteasome inhibitor. Proc ASCO 1999;18:209.
Berens ME, et al. Role of surgery in brain tumor management. In: Neurosurgery Clinics of North America, vol 1 (Rosenblum ML, ed.). WB Saunders, Philadelphia, 1990:1–18.
Salcman M. Survival in glioblastomas. Neurosurgery 1980;7:435–439.
Adams J, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333–338.
Tan C, Waldmann A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002;62:1083–1086.
Gardner RC, et al. Characterization of peptidyl boronic acid inhibitors of mammalian 20S and 26S proteasomes and their inhibition of proteasomes in cultured cells. Biochemistry 2000;346:447–454.
Goldberg AL, et al. New insights into proteasome function: from Archaebacteria to drug development. Chem Biol 1995;2:503–508.
Coux O, et al. Structure and function of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801–847.
King RW, et al. How proteolysis drives the cell cycle. Science 1996;274:1652–1659.
Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615–2622.
Palmobella VJ, et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritiis. Proc Natl Acad Sci USA 1998;95:15671–15676.
Sunwoo JB, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-KB, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001 ;7 :1419–1428.
Hideshima T, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–3076.
Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615–2622.
Bashir R, et al. Regrowth pattterns of glioblastoma multiforme related to planning of interestial brachytherapy radiation fields. Neurosurgery 1988;23:27–30.
Shiffer D, et al. Histological observations on the growth of malignant gliomas after radiotherapy and chemotherapy. Acta Neuropathol 1982;58:291–299.
Tsuboi K, et al. Regrowth patterns of supratentorial gliomas: estimation from computed tomographic scans. Neurosurgery 1986;19:946–951.
Larson DA, Gutin PH. Brachytherapy. In: Rationale, Techniques and Expectations in Malignant Cerebral Glioma (Apuzzo MJ, ed.). AANS, Park Ridge, IL, 1990:173–180.
Greenberg HS, et al. Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg 1984;61:423–429.
Brem H, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74:441–446.
Sneed PK, et al. Interstitial irradiation and hyperthermia for the treatment of recurrent malignant brain tumors. Neurosurgery 1991;28:206–215.
Leksel DG.In: Stereotactic Neurosurgery (Heilbrun MP, ed.).Williams & Wilkins, Baltimore, 1998:195–209.
Marks JE, Baglan RJ, Wong J. In: Biology of Brain Tumors (Walker MD, Thomas DGT, eds.) Martinus Nijhoff, Netherlands, 1986:325–339.
Matsukado Y, MacCarty CS, Kernohan JW. J Neurosurg 1981;18:636–644.
Schiffer D. In: Neurobiology of Brain Tumors (Salcman M, ed). Williams & Wilkins, Baltimore, 1991:85–135.
Kitajima I, et al. Ablation of transplanted HTLV-1 Tax transformed tumors in mice by antisense inhibition of NF-κ. Science 1992;258:1792–1795.
Maki CG, et al. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996;56:2649–2654.
Teicher BA, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638–2645.
Nix D, et al. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. ASCO Proc 2001;20:86a.
Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998;36:91–102.
Englehard HH, Groothius DG. The blood-brain barrier: structure, function, and response to neoplasia. In: The Gliomas (Berger MS, Wilson CB, eds). WB Saunders, Philadelphia, 1999:115–121.
Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998;17:7151–7160.
Frankel A, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719–3728.
Logothetis CJ, et al. Dose dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients with androgen-independent prostate cancer treated with the proteasome inhibitor PS-341. Proc ASCO 2001;20:186a.
Erlichman C, et al. A Phase I trial of the proteasome inhibitor PS-341 in patients with advanced cancer. Proc ASCO 2001;20:85a.
Aghajanian C, et al. A phase I trial of the novel protesome inhibitor PS-341 in advanced solid tumor malignancies. Proc ASCO 2001;20:85a.
Sun J, et al. CEP1612, a depeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res 2001;61:1280–1284.
Hamilton AL, et al. Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. Proc ASCO 2001;20:85a.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Olson, J.J., Bowers, G., Zhang, Z. (2004). Proteasome Inhibitor Therapy in a Brain Tumor Model. In: Adams, J. (eds) Proteasome Inhibitors in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-794-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-59259-794-9_13
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-452-4
Online ISBN: 978-1-59259-794-9
eBook Packages: Springer Book Archive